Zacks Investment Research Lowers Aldeyra Therapeutics, Inc. (ALDX) to Sell

Zacks Investment Research cut shares of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) from a hold rating to a sell rating in a research note published on Tuesday.

According to Zacks, “Aldeyra Therapeutics, Inc. is a biotechnology company. The company’s products target immune-mediated, inflammatory, orphan, and other diseases. It is developing NS2, a compound that binds and traps free aldehydes. Aldeyra Therapeutics, Inc. is based in Burlington, Massachusetts. “

Several other research firms have also recently issued reports on ALDX. HC Wainwright set a $18.00 price objective on shares of Aldeyra Therapeutics and gave the company a buy rating in a research report on Thursday, June 15th. ValuEngine cut shares of Aldeyra Therapeutics from a sell rating to a strong sell rating in a research report on Wednesday, September 6th. Cowen and Company reissued an outperform rating and issued a $14.00 price objective (up from $9.00) on shares of Aldeyra Therapeutics in a research report on Thursday, September 14th. Finally, Canaccord Genuity reissued a buy rating and issued a $27.00 price objective (up from $12.00) on shares of Aldeyra Therapeutics in a research report on Wednesday, September 13th. Two research analysts have rated the stock with a sell rating and four have given a buy rating to the stock. The stock presently has a consensus rating of Hold and an average price target of $15.95.

Shares of Aldeyra Therapeutics (NASDAQ:ALDX) traded down 0.68% during mid-day trading on Tuesday, reaching $7.25. 6,863 shares of the company’s stock traded hands. The firm’s market capitalization is $45.28 million. Aldeyra Therapeutics has a 12-month low of $3.80 and a 12-month high of $11.90. The stock has a 50-day moving average price of $6.48 and a 200 day moving average price of $5.08.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.02. Analysts anticipate that Aldeyra Therapeutics will post ($1.51) EPS for the current fiscal year.

WARNING: This article was originally reported by Ticker Report and is the property of of Ticker Report. If you are viewing this article on another site, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The legal version of this article can be read at https://www.tickerreport.com/banking-finance/2957463/zacks-investment-research-lowers-aldeyra-therapeutics-inc-aldx-to-sell.html.

In related news, major shareholder Life Sciences Maste Perceptive acquired 200,000 shares of the stock in a transaction on Tuesday, September 19th. The stock was bought at an average cost of $7.25 per share, with a total value of $1,450,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 28.40% of the stock is owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in the business. Perceptive Advisors LLC boosted its position in Aldeyra Therapeutics by 48.7% in the 1st quarter. Perceptive Advisors LLC now owns 2,885,458 shares of the biotechnology company’s stock valued at $12,897,000 after buying an additional 945,000 shares during the period. Sphera Funds Management LTD. lifted its position in shares of Aldeyra Therapeutics by 31.0% in the 2nd quarter. Sphera Funds Management LTD. now owns 875,931 shares of the biotechnology company’s stock worth $4,117,000 after purchasing an additional 207,431 shares during the period. Vanguard Group Inc. lifted its position in shares of Aldeyra Therapeutics by 3.2% in the 2nd quarter. Vanguard Group Inc. now owns 304,633 shares of the biotechnology company’s stock worth $1,431,000 after purchasing an additional 9,407 shares during the period. Sabby Management LLC purchased a new stake in shares of Aldeyra Therapeutics in the 1st quarter worth approximately $898,000. Finally, Hikari Power Ltd lifted its position in shares of Aldeyra Therapeutics by 186.4% in the 2nd quarter. Hikari Power Ltd now owns 107,858 shares of the biotechnology company’s stock worth $507,000 after purchasing an additional 70,196 shares during the period. 40.06% of the stock is owned by institutional investors.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.

Get a free copy of the Zacks research report on Aldeyra Therapeutics (ALDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aldeyra Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.